张岩,研究员,博士生导师
北京大学医学部心血管研究所PI
血管稳态与重构全国重点实验室PI
北京大学博雅特聘教授
国家基金委杰青
国家万人计划青年拔尖人才
张岩研究员主要从事心血管生理和病生理学研究,研究方向是心肌细胞损伤和保护机制。作为课题负责人获得国家自然科学基金5项,科技部国家重点研发计划子课题1项。发表论文54篇,其中第一作者/通讯作者27篇,包括Nature,Cell,Nature Medicine,Nature Cell Biology,和Circulation等。作为发明人获授权国家发明专利7项。现为中国病理生理学会血管医学专业委员会委员、青年工作小组副主任,中国病理生理学会受体专业委员会青年委员,中国遗传学会衰老遗传学分会委员,中国老年学和老年医学学会老年病学分会常委,北京医学会心血管分会委员、心血管基础研究学组副组长,中国人体健康科技促进会血压防控与研究专业委员会副主任委员,海峡两岸医药卫生交流协老年医学专委会常委等。
联系方式:
电话:010-82805945
Email: zhangyan9876@pku.edu.cn
地址:北京市海淀区学院路38号北京大学医学部医学科技楼北楼B1102
教育背景:
2003/9 – 2008/7北京大学医学部生理学博士(导师:肖瑞平教授)
1998/9– 2003/7北京大学医学部临床医学学士
工作经历:
2020/10 –至今北京大学医学部心血管研究所研究员
2010/10–2020/9北京大学分子医学研究所副研究员
2008/10 –2010/9北京大学分子医学研究所博士后
2005/10 –2007/10美国新泽西医科和牙科大学
细胞生物和分子医学系博士后
学术任职:
2014 -至今中国药理学会心脑血管药理专业委员会青年委员
2016 -至今北京生理科学会血管医学专业委员会血管生物学组副组长
2016 -至今北京生理科学会心血管病专业委员会药物与药物基因组学组委员
2016 -至今中国病理生理学会受体专业委员会青年委员
2017 -至今《中国心血管病杂志》编委
2018 -至今海峡两岸医药卫生交流协会老年医学专委会常委
2022 -至今北京医学会心血管分会委员
2020 -至今中国人体健康科技促进会血压防控与研究专业委员会副主任委员
2021 -至今中国病理生理学会血管医学专业委员会委员、青年工作小组副主任
2023 -至今中国遗传学会衰老遗传学分会委员
研究项目:
1.心肌细胞程序性死亡与心脏疾病。国家自然科学基金杰出青年项目;项目编号:82325004;起止日期:2024/1-2028/12;项目负责人;经费:400万元;在研
2. CaMKII-δ9在心脏缺血/再灌损伤及其修复中的作用与机制研究。国家自然科学基金重大研究计划培育项目;项目编号:92168114;起止日期:2022/1-2024/12;项目负责人;直接经费:80万元;在研。
3. 心肌纤维化演变机理探索与无创精准影像评价体系构建。国家重点研发计划工程科学与综合交叉专项;项目编号:2021YFF0501401;起止日期:2021/12-2026/12;参与人;经费:492.5万元;在研。
4. 物种内和物种间心脏与肝脏再生的分子调控网络及其异同机制研究。科技部国家重点研发计划;项目编号:2018YFA0800500;起止日期:2019/7-2024/6;子课题负责人;经费:519万元(子课题经费,个人经费167.61万元);在研。
5. 心脏保护。第四批国家万人计划青年拔尖人才;起止日期:2019/1-2022/12;项目负责人;经费:220万元;结题。
6. 心肌细胞程序性坏死(坏死性凋亡)的调节机制研究。北京市自然科学基金面上项目;项目编号:5182010;起止日期:2018/1-2020/12;项目负责人;经费:20万元;结题。
7. 心肌细胞程序性坏死的调节通路研究。国家自然科学基金面上项目;项目编号:31671177;起止日期:2017/1-2020/12;项目负责人;直接经费:60万元;结题。
8. 受体相互作用蛋白3(RIP3)在心肌细胞损伤中的作用。国家自然科学基金面上项目;项目编号:81370234;起止日期:2014/1-2017/12;项目负责人;经费:60万元;结题。
9. 钙/钙调素依赖的蛋白激酶II在阿霉素心肌病中的作用。国家自然科学基金面上项目;项目编号:81170100;起止日期:2012/1-2015/12;项目负责人;经费:60万元;结题。
10. MG53在糖尿病心肌病中的作用。国家自然科学基金重点项目;项目编号:81130073;起止日期:2012/1-2016/12;参与人(项目负责人:肖瑞平);经费:260万元;结题。
11. 阿霉素心肌病中钙/钙调素依赖的蛋白激酶II的功能研究。高等学校博士学科点专项科研基金(新教师类);项目编号:20110001120119;项目负责人;经费:4万元;结题。
12. MG53在心脏缺血后适应保护中的作用。国家自然科学基金青年项目;项目编号:81000054;起止日期:2011/1-2011/12;项目负责人;经费:10万元;结题。
13. MG53在心脏缺血后适应保护中的作用。中国博士后科学基金特别资助;第三批;项目负责人;经费:10万元;结题。
获奖情况:
1. 2023年获林松年杰出青年学者奖
2. 2023年获北京大学2022-2023学年招生先进个人
3. 2022年获第十六届东方心脏病学会议“东方新星”奖
4. 2019年获北京大学绿叶生物医药杰出青年学者奖
5. 2016年中国心脏大会(CHC)青年科学家奖提名奖
6. 2016年Bayer Investigator award
7. 2013年获中国生理学会第37届国际生理科学联合会会议资助
8. 2012年获北京大学绿叶生物医药杰出青年学者奖
9. 2011年获中国生理学会张锡钧基金会第十一届全国青年优秀生理学论文奖二等奖
10. 2010年获北京大学优秀博士后称号
11. 2010年获国际心脏研究会(ISHR)第二十届世界大会Richard J Bing青年科学家奖•决赛奖
专利:
1. 国家发明专利:曹春梅,张岩,肖瑞平,麻建杰。MG53蛋白预防和/或治疗心脏缺血/再灌损伤的用途。中国专利号:ZL.2009 1 0241451.3。
2. 国家发明专利:肖瑞平,曹春梅,张岩,宋瑞生。MG53基因在治疗胰岛素抵抗和II型糖尿病及其相关病症中的应用。中国专利号: ZL.2010 1 0240983.8.
3. 国家发明专利:肖瑞平,曹春梅,张岩,吕凤祥。一种MG53突变体及其突变方法和应用。中国专利号:ZL.2013 1 0047584.3。
4. 国家发明专利:肖瑞平,曹春梅,张岩,吕凤祥。密码子优化的MG53蛋白的编码核苷酸序列、其重组体及其应用。中国专利号:ZL.2014 1 0080068.5。
5. 国家发明专利:肖瑞平,吕凤祥,张岩,胡新立。检测或抑制细胞外游离MG53的方法和用途。中国专利号:ZL201811248264.3。(国际申请号:PCT/CN2018/109871)
6. 国家发明专利:张岩、雷晓光、张俊霞、肖瑞平。吲哚啉酮类化合物及其在心肌损伤中的应用。中国专利号:ZL202210049648.2。
7. 国家发明专利:肖瑞平,吕凤祥,张岩,郭寺乐。MG53突变体及其制备方法和用途。中国专利申请号:201780003946.5。(国际申请号:PCT/CN2017/093640)
8. 国际发明专利:张茂,张岩,肖瑞平,高华。ANTAGONISTS OF CAMKII-DELTA 9 AND USES THEREOF。国际专利申请号:PCT/CN2019/103678。
9. 国家发明专利:吴则开、石源、崔月利、张博、汤富酬、王世强、张岩。ANGPT4 蛋白及其编码基因在调控心脏损伤后的修复与再生能力中的应用。中国专利号:ZL202111064028.8。
10. 国家发明专利:张岩、张辛、卢珊、黄洪杰、曹宸熹。培非替尼或其药学上可接受的盐的新用途。中国专利号:ZL202310286561.1。
发表文章:
第一/通讯作者文章:
1. Wang WW#, Ji SY#, Zhang W#, Zhang J#, Cai C#, Hu R#, Zang SK, Miao L, Xu H, Chen LN, Yang Z, Guo J, Qin J, Shen DD, Liang P, Zhang Y(张岩)*, Zhang Y*.Structure-based design of non-hypertrophic apelin receptor modulator. Cell. 2024,in press.(*共同通讯作者,影响因子64.5).
2. WuZ#, Shi Y#, Cui Y, Xing X, Zhang L, Liu D, Zhang Y, Dong J, Jin L, Pang M, Xiao RP, Zhu Z, Xiong JW, Tong X, Zhang Y(张岩)*, Wang S*, Tang F*, Zhang B*. Single-cell analysis reveals an Angpt4-initiated EPDC-EC-CM cellular coordination cascade during heart regeneration. ProteinCell. 2023,14, 350-368.(*共同通讯作者,影响因子21.1).
3. Dong H#, Zhang Y(张岩)#, Sun D, Wang G, Zhang Q, Hidru TH, Yang Y, Wang S, Wei Y, Liu F, Zhang J, Xia Y*, Yang X*. Refining prediction of stroke in sinus node dysfunction patients without atrial fibrillation using a P-combined score: a multi-centre study. Eur J Prev Cardiol. 2023,in press.(*共同第一作者,影响因子8.3).
4. Zhang J, Liang R, Wang K, Zhang W, Zhang M, Jin L, Xie P, Zheng W, Shang H, Hu Q, Li J, Chen G, Wu F, Lan F, Wang L, Wang S.Q., Li Y, Zhang Y, Liu J, Lv F, Hu X, Xiao R.P., Lei X*,Zhang Y(张岩)*. Novel CaMKII-δ inhibitor hesperadin exerts dual functions to ameliorate cardiac ischemia/reperfusion injury and inhibit tumor growth. Circulation.2022,145, 1154-1168. (*共同通讯作者,影响因子37.8).
5. Yao Y#, Li F#, Zhang M#, Jin L, Xie P, Liu D, Zhang J, Hu X, Lv F, Shang H, Zheng W, Sun X, Duanmu J, Wu F, Lan F, Xiao RP.,Zhang Y(张岩)*. Targeting CaMKII-δ9 Ameliorates Cardiac Ischemia/reperfusion Injury by Inhibiting Myocardial Inflammation. Circ Res.2022, 130, 887-903. (*独立通讯作者,影响因子20.1).
6. Feng H#, Shen H#, Robeson MJ, Wu YH, Wu HK., Chen GJ, Zhang S, Xie P, Jin L, He Y, Wang Y, Lv F, Hu X, Zhang Y(张岩)*, Xiao RP.*. MG53 E3 ligase-dead mutant protects diabetic hearts from acute ischemic/reperfusion injury and ameliorates diet-induced cardiometabolic damage. Diabetes. 2022, 71, 298-314. (*共同通讯作者,影响因子7.7).
7. Zhang M#, Zhang J#, Zhang W, Hu Q, Jin L, Xie P, Zheng W, Shang H, Zhang Y(张岩)*. CaMKII-δ9 induces cardiomyocyte death to promote cardiomyopathy and heart failure. Front Cardiovasc Med.2022, 8, 820416. (*独立通讯作者,影响因子3.6).
8. Song Y, Xu C, Liu J, Li Y, Wang H, Shan D, Wainer I, Hu X, Zhang Y(张岩)*, Woo YH*, Xiao RP. Heterodimerization with 5-HT2BR is indispensable for b2AR-mediated cardioprotection. Circ Res. 2021,128, 262-277 (*共同通讯作者,影响因子20.1).
9. Cao C#, Zhang Y(张岩)#, Cheng J, Wu F, Niu X, Hu X, Duan X, Fu X, Zhang J, Zhang X*, Ao Y*. β-Arrestin2 Inhibits the Apoptosis and Facilitates the Proliferation of Fibroblast-like Synoviocytes in Diffuse-type Tenosynovial Giant Cell Tumor. Cancer Genomics Proteomics. 2021, 18, 461-471(#共同第一作者,影响因子2.5).
10. Shan D#, Guo S#, Wu HK, Lv F, Jin L, Zhang M, Xie P, Wang Y, Song Y, Wu F, Lan F, Hu X, Cao CM*, Zhang Y(张岩)*, Xiao RP*. Cardiac ischemic preconditioning promotes MG53 secretion through H2O2-activated PKC-dsignaling. Circulation. 2020,142, 1077-1091 (*共同通讯作者,影响因子37.8).
11. Zhang M, Gao H, Liu D, Zhong X, Shi X, Yu P, Jin L, Liu Y, Tang Y, Song Y, Liu J, Hu X, Li CY, Song L, Qin J, Wu F, Lan F, Zhang Y(张岩)*, Xiao RP. CaMKII-d9 promotes cardiomyopathy through disrupting UBE2T-dependent DNA repair. Nat Cell Biol. 2019, 21, 1152-1163 (*独立通讯作者,影响因子21.3).
12. Wu HK#, Zhang Y(张岩)#, Cao CM#, Hu X, Fang M, Yao Y, Jin L, Chen G, Jiang P, Zhang S, Song R, Peng W, Liu F, Guo J, Tang L, He Y, Shan D, Huang J, Zhou Z, Wang D, Lv F*, Xiao RP*. Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis. Circulation. 2019, 139, 901-914 (#共同第一作者,影响因子37.8).
13. Wang Y, Jin L, Song Y, Zhang M, Shan D, Liu Y, Lv F, Xiao RP, Zhang Y(张岩)*. β-arrestin 2 mediates cardiac ischemia-reperfusion injury via inhibiting GPCR-independent cell survival signaling. Cardiovasc Res. 2017, 113, 1615-1626 (*独立通讯作者,影响因子10.8).
14. Zhang T#, Zhang Y(张岩)#*, Cui M, Jin L, Wang Y, Lv F, Liu Y, Zheng W, Shang H, Zhang J, Zhang M, Wu HK, Guo J, Zhang X, Hu X, Cao CM, Xiao RP*. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med. 2016, 22, 175-182 (*共同通讯作者,#共同第一作者,影响因子82.9).
15. Zhang Y(张岩), Zheng W, Liu Y, Wang J, Peng Y, Shang H, Hou N, Hu X, Ding Y, Xiao Y, Wang C, Zeng F, Mao J, Zhang J, Ma D, Sun X, Li C, Xiao RP, Zhang X. Eplerenone restores 24-h blood pressure circadian rhythm and reduces advanced glycation end-products in rhesus macaques with spontaneous hypertensive metabolic syndrome. Sci Rep. 2016, 6, 23957(第一作者,影响因子4.6).
16. Zhu W#, Tsang S#, Browe, DM#, Woo AY, Huang Y, Xu C, Liu JF, Lv F, Zhang Y(张岩)*, Xiao RP*. Interaction of β1-adrenoceptor with RAGE mediates cardiomyopathy via CaMKII signaling. JCI Insight.2016, 1, e84969(*共同通讯作者,影响因子8.0).
17. Song RS#, Peng W#, Zhang Y(张岩)#, Lv F, Wu HK, Guo J, Cao Y, Pi Y, Zhang X, Jin L, Zhang M, Jiang P, Liu F, Meng S, Zhang X, Jiang P, Cao CM*, Xiao RP*. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature.2013, 494, 375-379 (#共同第一作者,影响因子64.8).
18. Zhang Y(张岩)#, Lv F#, Jin L, Peng W, Song RS, Ma J, Cao CM*, Xiao RP*. MG53 participates in ischemic postconditioning through the RISK signaling pathway.Cardiovasc Res. 2011, 91, 108-115 (#共同第一作者,影响因子10.8).
19. Cao CM#, Zhang Y(张岩)#, Weisleder N#, Ferrante C, Wang X, Lv F, Zhang Y, Song R, Hwang M, Jin L, Guo J, Peng W, Li G, Nishi M, Takeshima H, Ma J*, Xiao RP*. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010, 121, 2565-2574 (#共同第一作者,影响因子37.8).
20. Peng W#, Zhang Y(张岩)#, Zheng M, Cheng H, Zhu W, Cao CM*, Xiao RP*. Cardioprotection by CaMKII-δB is mediated by phosphorylation of HSF1 and subsequent expression of inducible HSP70. Circ Res. 2010, 106, 102-110 (#共同第一作者,影响因子20.1).
普通作者文章:
1. Fang M, Wu HK, Pei Y, Zhang Y(张岩), Gao X, He Y, Chen G, Lv F, Jiang P, Li Y, Li W, Jiang P, Wang L, Ji J, Hu X, Xiao RP.E3 ligase MG53 suppresses tumor growth by degrading cyclin D1. Signal Transduct Target Ther. 2023, 8, 263(影响因子39.3)
2. Lv F, Wang Y, Shan D, Guo S, Chen G, Jin L, Zheng W, Feng H, Zeng X, Zhang S, Zhang Y(张岩), Hu X, Xiao RP.Blocking MG53S255 Phosphorylation Protects Diabetic Heart From Ischemic Injury. Circ Res. 2022, 131,962-976(影响因子20.1)
3. Zhou X, Zhang C, Wu X, Hu X, Zhang Y(张岩), Wang X, Zheng L, Gao P, Du J, Zheng W, Shang H, Hu K, Jiang Z, Nie Y, Hu S, Xiao RP, Zhu X, Xiong JW.Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction. Nat Commun. 2022, 13, 6672(影响因子16.6)
4. Feng Y, Xu H, Liu J, Xie N, Gao L, He Y, Yao Y, Lv F,Zhang Y(张岩), Lu J, Zhang W, Li CY, Hu X, Yang Z, Xiao RP. Functional and Adaptive Significance of Promoter Mutations That Affect Divergent Myocardial Expressions of TRIM72 in Primates. Mol Biol Evol. 2021, 38, 2930-2945(影响因子10.7)
5. Jiang P, Ren L, Zhi L, Yu Z, Lv F, Xu F, Peng W, Bai X, Cheng K, Quan L, Zhang X, Wang X, Zhang Y(张岩), Yang D, Hu X, Xiao RP. Negative regulation of AMPK signaling by high glucose via E3 ubiquitin ligase MG53.Mol Cell.2021, 81, 629-637 (影响因子16.0)
6. Wang J, Zhang J, Lin X, Wang Y, Wu X, Yang F, Gao W, Zhang Y(张岩), Sun J, Jiang C, Xu M. DCA-TGR5 signaling activation alleviates inflammatory response and improves cardiac function in myocardial infarction.J Mol Cell Cardiol. 2020, 151, 3-14 (影响因子5.0).
7. Cao C, Wu F, Niu X, Hu X, Cheng J, Zhang Y(张岩), Li C, Duan X, Fu X, Zhang J, Zhang X, Ao Y.Cadherin-11 cooperates with inflammatory factors to promote the migration and invasion of fibroblast-like synoviocytes in pigmented villonodular synovitis.Theranostics. 2020, 10, 10573-10588 (影响因子12.4).
8. Hu XM, Li H, Chen X, Liu HH, Zuo W, Zhang Y(张岩), Zhang SY. Plasma concentration of receptor-interacting protein kinase-3 as a potential biomarker for diagnosis and prognosis in heart failure. Clin Chim Acta. 2020,509, 273-279(影响因子5.0).
9. Yang HQ, Wang LP, Gong YY, Fan XX, Zhu SY, Wang XT, Wang YP, Li LL, Xing X, Liu XX, Ji GS, Hou T, Zhang Y(张岩), Xiao RP, Wang SQ. β2-Adrenergic Stimulation Compartmentalizes β1 Signaling Into Nanoscale Local Domains by Targeting the C-Terminus of β1-Adrenoceptors. Circ Res. 2019, 124, 1350-1359 (影响因子20.1).
10. Wang C, Xiao Y, Wang J, Hou N, Cui W, Hu X, Zeng F, Yuan Y, Ma D, Sun X, Zhang Y(张岩), Zheng W, Liu Y, Shang H, Chen L, Xiao RP, Zhang X.Dynamic changes in insulin and glucagon during disease progression in rhesus monkeys with obesity-related type 2 diabetes mellitus.Diabetes Obes Metab. 2019, 21, 1111-1120(影响因子5.8).
11. Chen X, Li HY, Hu XM, Zhang Y(张岩), Zhang SY. Current understanding of gut microbiota alterations and related therapeutic intervention strategies in heart failure.Chin Med J (Engl). 2019,132, 1843-1855(影响因子6.1).
12. Zheng W, Liu Y, Shang H, Zhang Y(张岩), Ma D, Hou N, Wang J, Sun X, Peng Y, Pan L, Wang Z, Tang X, Xiao RP, Zhang X. Characterization of spontaneously-developed non-alcoholic fatty liver disease in aged rhesus monkeys.Diabetol Metab Syndr. 2018, 10, 68(影响因子4.8).
13. Zeng F, Wen W, Cui W, Zheng W, Liu Y, Sun X, Hou N, Ma D, Yuan Y, Shi H, Wang Z, Li Z, Xiao Y, Wang C, Li Y, Shang H, Li CY, Wang J, Zhang Y(张岩), Xiao RP, Zhang X. Central role of RIPK1-VDAC1 pathway on cardiac impairment in a non-human primate model of rheumatoid arthritis. J Mol Cell Cardiol. 2018, 125, 50-60 (影响因子5.0).
14. Xiao Y, Wang C, Chen JY, Lu F, Wang J, Hou N, Hu X, Zeng F, Ma D, Sun X, Ding Y, Zhang Y(张岩), Zheng W, Liu Y, Shang H, Zhu W, Han C, Zhang Y, Ouyang K, Chen L, Chen J, Xiao RP, Li CY, Zhang X. Deficiency of PRKD2 triggers hyperinsulinemia and metabolic disorders. Nat Commun. 2018, 9, 2015 (影响因子16.6)
15. Zeng F, Chen X, Cui W, Wen W, Lu F, Sun X, Ma D, Yuan Y, Li Z, Hou N, Zhao H, Bi X, Zhao J, Zhou J, Zhang Y(张岩), Xiao RP, Cai J, Zhang X. RIPK1 binds MCU to mediate induction of mitochondrial Ca2+ uptake and promote colorectal oncogenesis. Cancer Res. 2018,78, 2876-2885 (影响因子11.2).
16. Song C, Yan H, Wang H, Zhang Y(张岩), Cao H, Wan Y, Kong L, Chen S, Xu H, Pan B, Zhang J, Fan G, Xin H, Liang Z, Jia W, Tian XL. AQR is a novel type 2 diabetes-associated gene that regulates signaling pathways critical for glucose metabolism. J Genet Genomics. 2018, 45, 111-120 (影响因子5.9).
17. Xie N, Chen M, Dai R, Zhang Y(张岩), Zhao H, Song Z, Zhang L, Li Z, Feng Y, Gao H, Wang L, Zhang T, Xiao RP, Wu J, Cao CM. SRSF1 promotes vascular smooth muscle cell proliferation through a Δ133p53/EGR1/KLF5 pathway. Nat Commun. 2017, 8, 16016 (影响因子16.6)
18. Guo J, Xie N, Li G, Zhang Y(张岩), Lv F, Guo S, Feng Y, Cao CM, Xiao RP. p55γ functional mimetic peptide N24 blocks vascular proliferative disorders. J Mol Med (Berl). 2015, 93, 1107-1118(影响因子4.7)
19. Li G, Xie N, Yao Y, Zhang Y(张岩), Guo J, Feng Y, Lv F, Xiao RP, Cao CM. Identification of PI3K regulatory subunit p55γ as a novel inhibitor of vascular smooth muscle cell proliferation and neointimal formation. Cardiovasc Res. 2015, 105, 75-85(影响因子10.8)
20. Liu F, Song R, Feng Y, Guo J, Chen Y, Zhang Y, Chen T, Wang Y, Huang Y, Li CY, Cao C, Zhang Y (张岩), Hu X, Xiao RP. Upregulation of MG53 induces diabetic cardiomyopathy via transcriptional activation of PPAR-α. Circulation. 2015, 131, 795-804(影响因子37.8)
21. Ge L,Zhou X,Ji WJ,Lu RY,Zhang Y(张岩),Zhang YD,Ma YQ,Zhao JH,Li YM. Neutrophil extracellular traps in ischemia-reperfusion injury-induced myocardial no-reflow: therapeutic potential of DNase-based reperfusion strategy. Am J Physiol-Heart Circ Physiol.2015, 308, H500-509(影响因子4.8)
22. Weisleder N, Takizawa N, Lin P, Wang X, Cao CM,Zhang Y(张岩), Tan T, Ferrante C, Zhu H, Chen PJ, Yan R, Sterling M, Zhao X, Hwang M, Takeshima M, Cai C, Cheng H, Takeshima H, Xiao RP, Ma J. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.Sci Transl Med. 2012, 4, 139ra85(影响因子17.1).
23. Zhang XQ, Zhang RL, Raab S, Zheng W, Wang J, Liu N, Zhu TG, Xue LF, Song ZT, Mao JM, Li KT, Zhang HL, Zhang Y(张岩), Han C, Ding Y, Wang H, Hou N, Liu YL, Shang SJ, Li CY, Sebokova E, ChengHP, Huang PL. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone.Circulation. 2011,124, 77-86(影响因子37.8).
24. Li CY, Zhang Y, Wang Z, Zhang Y(张岩), Cao CM, Zhang PW, Lu SJ, Li XM, Yu Q, Zheng X, Du Q, Uhl GR, Liu QR, Wei L. A human-specific De Novo protein-coding gene associated with human brain functions. PLoS Comput Biol. 2010,6,e1000734 (影响因子4.3).
25. Shen YT, Depre C, Yan L, Park JY, Tian B, Jain K, Chen L, Zhang Y(张岩), Kudej RK, Zhao X, Sadoshima J, Vatner DE,. Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation.2008, 118, 1961-1969(影响因子37.8).
综述和述评:
1. Zhang W, Dong E, Zhang J*, Zhang Y(张岩)*. CaMKII, 'jack of all trades' in inflammation during cardiac ischemia/reperfusion injury. J Mol Cell Cardiol. 2023, 184, 48-60 (*共同通讯作者,影响因子5.0). (综述)
2. Zhang J, Liu D, Zhang M, Zhang Y(张岩)*. Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond. Brit J Pharmacol. 2019, 176, 4319-4339 (*独立通讯作者,影响因子7.3). (综述)
3. Wu HK#, Zhang Y(张岩)#, Chen G, Hu X, Lv F, Xiao RP*. Response to Letter Regarding Article, "Glucose-sensitive myokine/cardiokine MG53 regulates systemic insulin response and metabolic homeostasis". Circulation. 2019, 140, e188-e189 (#共同第一作者,影响因子37.8). (回复短评)
4. Zhang Y(张岩)*, Wu HK, Lv F, Xiao RP.MG53: biological function and potential as a therapeutic target. Mol Pharmacol.2017, 92, 211-218 (第一作者,独立通讯作者,影响因子3.6). (综述)
5. Zhang Y(张岩)*, Wu HK, Lv F, Xiao RP.MG53 is a double-edged sword for human diseases. Acta Physiologica Sinica.2016, 68, 505-516(第一作者,*独立通讯作者).(综述)
6. Zhang Y(张岩), Zhang T, Cao CM, Xiao RP*. mTOR: Good, Bad, or Ugly? Cardiovasc Res. 2012, 95, 261-262 (第一作者,影响因子10.9). (述评)
7. Zhang Y(张岩), Cao CM, Xiao RP*. Kinase activity-independent anchoring function of Protein Kinase C-d. Am J Physiol-Cell Ph. 2010, 299, C733-735 (第一作者,影响因子5.5).(述评)
8. Zhou X, Ji WJ, Ge L, Lu RY, Zhang Y(张岩), Zhang YD, Ma YQ, Zhao JH, Li YM. Reply to "Letter to the editor: Intravital imaging of the association between intravascular neutrophil extracellular traps and microvascular obstruction using multiphoton microscopy".Am J Physiol-Heart Circ Physiol, 2015, 308, H961-962 (影响因子4.8). (回复短评)
9. Peng W, Zhang Y(张岩), Cao CM, Xiao RP. AMPK and TNF-a at the crossroad of cell death and survival in ischemic heart. Cardiovasc Res. 2009, 84, 1-3 (影响因子10.9).(述评)
1